SSA
VRDN icon

Schonfeld Strategic Advisors’s Viridian Therapeutics VRDN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
+793,508
New +$12.8M 0.05% 310
2026
Q1 		– Sell
-217,434
Closed -$6.56M – 2716
2025
Q4 		$6.56M Buy
217,434
+159,506
+275% +$4.37M 0.03% 465
2025
Q3 		$1.11M Sell
57,928
-80,823
-58% -$1.46M 0.01% 1312
2025
Q2 		$1.94M Buy
138,751
+57,242
+70% +$777K 0.01% 1007
2025
Q1 		$1.1M Sell
81,509
-589,091
-88% -$10M 0.01% 1244
2024
Q4 		$12.9M Sell
670,600
-92,518
-12% -$2.01M 0.07% 246
2024
Q3 		$17.4M Buy
763,118
+617,365
+424% +$10.1M 0.12% 172
2024
Q2 		$1.9M Sell
145,753
-18,260
-11% -$253K 0.01% 933
2024
Q1 		$2.87M Sell
164,013
-14,906
-8% -$289K 0.02% 859
2023
Q4 		$3.9M Buy
178,919
+70,882
+66% +$1.12M 0.03% 585
2023
Q3 		$1.66M Buy
108,037
+84,670
+362% +$1.62M 0.01% 878
2023
Q2 		$556K Buy
+23,367
New +$599K ﹤0.01% 1184
2023
Q1 		– Sell
-31,400
Closed -$917K – 2690
2022
Q4 		$917K Sell
31,400
-21,223
-40% -$489K 0.01% 1198
2022
Q3 		$945K Buy
+52,623
New +$946K 0.01% 1308
2022
Q1 		– Sell
-21,512
Closed -$425K – 2947
2021
Q4 		$425K Sell
21,512
-22,488
-51% -$419K ﹤0.01% 1343
2021
Q3 		$724K Buy
+44,000
New +$645K 0.01% 1099

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Schonfeld Strategic Advisors's VRDN Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 793,508 shares worth $14.6M. The stake represents 0.05% of the portfolio and ranks #310 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in VRDN as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in VRDN in Q3 2021 and has held it in 16 quarters since. The position peaked at $17.4M in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Schonfeld Strategic Advisors held 793,508 shares of Viridian Therapeutics worth $14.6M as of Q2 2026.
  • Viridian Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Viridian Therapeutics made up 0.05% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #310 holding.
  • Schonfeld Strategic Advisors first reported a position in Viridian Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Schonfeld Strategic Advisors's Viridian Therapeutics position peaked at $17.4M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.